Fitch has raised to “positive” the outlook on the ’A+’ rating of SCOR SE and its main subsidiaries.
SCOR's first half of 2014 results.
SCOR delivers a strong performance for the first half 2014 with net income of EUR 256 million, up 35% from H1 2013
SCOR delivers a strong performance for the first half 2014 with net income of EUR 256 million, up 35% from H1 2013
Details about the liquidity account at 30 june 2014 and of the last half-year statement
NUEVOS ENFOQUES DEL LED (LUPUS ERITEMATOSO DISEMINADO) El lupus es una patología asociada a un pro blema inmunitario.
NUOVI ASPETTI DEL LES (LUPUS ERITEMATOSO SISTEMICO) Il lupus è una patologia legata ad un disturbo immunitario.
Lupus is a disease caused by a disorder of the immune system. Its pathophysiological mechanisms, which include genetic, immunological and environmental factors, remain poorly understood. This is a rare disease.
The new Cologne-Zurich Hub will maintain the existing two locations of Cologne and Zurich, under a single management team.
The Trading Risk Awards ceremony is held each year to acknowledge the hard work and professionalism of the (re)insurance convergence market.
Organised each year by Reactions magazine, these awards distinguish companies and individuals operating in the London market, as voted by worldwide insurance and reinsurance market professionals.
The SCOR Group was awarded the “Prix de la meilleure opération financière – M&A” (Prize for the Best Financial Operation) for 2013 by the Club des Trente, for its acquisition of Generali US.